FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2494092938> ?p ?o ?g. }

• W2494092938 abstract "Abstract Abstract 3390 Poster Board III-278 Introduction: While the outcome of children with acute lymphoblastic leukemia (ALL) has steadily improved, the prognosis for those who relapse (rALL) remains poor. Partly this has been due to the lack of a standardised approach to children with rALL. The international collaborative trial ALLR3 stratified patients into standard (SR), intermediate (IR) and high risk (HR) groups based on the time from first diagnosis to relapse, site of relapse and immunophenotype. All patients received 3 blocks of therapy, with a minimal residual disease (MRD) assessment at the end of blocks 1 and 3. Allogeneic stem cell transplantation (allo-SCT) was offered to all HR and those IR who had a MRD of ≥10-4 at week 5. In children in whom MRD was unavailable, allo-SCT was offered to those who relapsed within 24 months of stopping therapy. All other patients continued on chemotherapy for 24 months. A day 1 and 2 randomisation was performed between mitoxantrone and idarubicin. Results: 239 patients were enlisted, of whom 216 were randomised and 109 idarubicin and 103 mitoxantrone patients are analysable. There were non-significant differences between the groups with regards to time to relapse, site of relapse and cytogenetic subtypes.108 (51%) were in CR2 at a median follow up of 36 months (range 1-70) and Progression Free Survival (PFS) at 3 years was 50.3% (95% CI 42.9%, 57.3%). Forty four percent of idarubicin and 40% of mitoxantrone patients had disease levels of ≥10-4 at week 5 (p=0.90) at the end of block 1. The PFS at 3 years for those who received idarubicin was 35.9% (25.9%, 45.9%) and mitoxantrone 64.6% (54.2%, 73.2%) (p=0.0004). Adjusted for differences in risk group, country, age, gender and cytogenetic subtype, this difference continues to be significant (p=0.003). Overall mitoxantrone was better tolerated and less toxic than idarubicin. A competing risks model showed that the difference between the two drugs is primarily related to disease control (p=0.02), rather than toxicity of treatment (p=0.09). In the patients who were transplanted, 35% and 5% of patients who received idarubicin (n = 48) or mitoxantrone (n = 44) respectively have relapsed. Based on the intention to treat analyses, there were non significant differences in patients treated without an allo-SCT in both arms. IR patients who were transplanted did worse (p = 0.01) in the idarubicin group but had comparable results in the mitoxantrone group to those who received chemotherapy. As a result the randomisation in ALLR3 has now been closed, though the study continues to accrue to better answer the MRD stratification question. Conclusions: Mitoxantrone is a well tolerated and highly effective drug for the treatment of children with rALL. While MRD at week 5 failed to predict the differences in outcome for the two randomised groups, it identified that children in the IR group with <10-4 could be treated without an allo-SCT. Disclosures: Off Label Use: Although Idarubicin and Mitoxantrone have been shown to be effective in ALL, they are not licensed for use in children in the UK. ." @default.
• W2494092938 created "2016-08-23" @default.
• W2494092938 creator A5003290478 @default.
• W2494092938 creator A5006016287 @default.
• W2494092938 creator A5010587672 @default.
• W2494092938 creator A5031395974 @default.
• W2494092938 creator A5032713965 @default.
• W2494092938 creator A5046777353 @default.
• W2494092938 creator A5050141938 @default.
• W2494092938 creator A5052024539 @default.
• W2494092938 creator A5053476959 @default.
• W2494092938 creator A5066362816 @default.
• W2494092938 creator A5076557705 @default.
• W2494092938 creator A5080449822 @default.
• W2494092938 creator A5085154817 @default.
• W2494092938 date "2009-11-20" @default.
• W2494092938 modified "2023-10-01" @default.
• W2494092938 title "Mitoxantrone, Not Idarubicin, Significantly Improves the Outcome of Children with Relapsed ALL – Result of the International, Randomised ALLR3 Study." @default.
• W2494092938 doi "https://doi.org/10.1182/blood.v114.22.3390.3390" @default.
• W2494092938 hasPublicationYear "2009" @default.
• W2494092938 type Work @default.
• W2494092938 sameAs 2494092938 @default.
• W2494092938 citedByCount "0" @default.
• W2494092938 crossrefType "journal-article" @default.
• W2494092938 hasAuthorship W2494092938A5003290478 @default.
• W2494092938 hasAuthorship W2494092938A5006016287 @default.
• W2494092938 hasAuthorship W2494092938A5010587672 @default.
• W2494092938 hasAuthorship W2494092938A5031395974 @default.
• W2494092938 hasAuthorship W2494092938A5032713965 @default.
• W2494092938 hasAuthorship W2494092938A5046777353 @default.
• W2494092938 hasAuthorship W2494092938A5050141938 @default.
• W2494092938 hasAuthorship W2494092938A5052024539 @default.
• W2494092938 hasAuthorship W2494092938A5053476959 @default.
• W2494092938 hasAuthorship W2494092938A5066362816 @default.
• W2494092938 hasAuthorship W2494092938A5076557705 @default.
• W2494092938 hasAuthorship W2494092938A5080449822 @default.
• W2494092938 hasAuthorship W2494092938A5085154817 @default.
• W2494092938 hasConcept C126322002 @default.
• W2494092938 hasConcept C141071460 @default.
• W2494092938 hasConcept C143998085 @default.
• W2494092938 hasConcept C2776694085 @default.
• W2494092938 hasConcept C2778041864 @default.
• W2494092938 hasConcept C2778461978 @default.
• W2494092938 hasConcept C2779117419 @default.
• W2494092938 hasConcept C2779823535 @default.
• W2494092938 hasConcept C2780923524 @default.
• W2494092938 hasConcept C2911091166 @default.
• W2494092938 hasConcept C71924100 @default.
• W2494092938 hasConceptScore W2494092938C126322002 @default.
• W2494092938 hasConceptScore W2494092938C141071460 @default.
• W2494092938 hasConceptScore W2494092938C143998085 @default.
• W2494092938 hasConceptScore W2494092938C2776694085 @default.
• W2494092938 hasConceptScore W2494092938C2778041864 @default.
• W2494092938 hasConceptScore W2494092938C2778461978 @default.
• W2494092938 hasConceptScore W2494092938C2779117419 @default.
• W2494092938 hasConceptScore W2494092938C2779823535 @default.
• W2494092938 hasConceptScore W2494092938C2780923524 @default.
• W2494092938 hasConceptScore W2494092938C2911091166 @default.
• W2494092938 hasConceptScore W2494092938C71924100 @default.
• W2494092938 hasLocation W24940929381 @default.
• W2494092938 hasOpenAccess W2494092938 @default.
• W2494092938 hasPrimaryLocation W24940929381 @default.
• W2494092938 hasRelatedWork W2296132622 @default.
• W2494092938 hasRelatedWork W2529976270 @default.
• W2494092938 hasRelatedWork W2545597103 @default.
• W2494092938 hasRelatedWork W2556675457 @default.
• W2494092938 hasRelatedWork W2558068727 @default.
• W2494092938 hasRelatedWork W2558853238 @default.
• W2494092938 hasRelatedWork W2576717688 @default.
• W2494092938 hasRelatedWork W2577543928 @default.
• W2494092938 hasRelatedWork W2581392108 @default.
• W2494092938 hasRelatedWork W2583894790 @default.
• W2494092938 hasRelatedWork W2586089700 @default.
• W2494092938 hasRelatedWork W2588485349 @default.
• W2494092938 hasRelatedWork W2910434161 @default.
• W2494092938 hasRelatedWork W2979454769 @default.
• W2494092938 hasRelatedWork W2979610496 @default.
• W2494092938 hasRelatedWork W2979796411 @default.
• W2494092938 hasRelatedWork W2985918529 @default.
• W2494092938 hasRelatedWork W3011299721 @default.
• W2494092938 hasRelatedWork W3013984209 @default.
• W2494092938 hasRelatedWork W378987734 @default.
• W2494092938 isParatext "false" @default.
• W2494092938 isRetracted "false" @default.
• W2494092938 magId "2494092938" @default.
• W2494092938 workType "article" @default.